Resources from the same session
2609 - Overall survival (OS) in KATE2, a phase 2 study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Presenter: Leisha Emens
Session: Proffered Paper - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
6571 - Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
Presenter: Hope Rugo
Session: Proffered Paper - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1103 - KEYNOTE-119: Phase 3 study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC)
Presenter: Javier Cortés
Session: Proffered Paper - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
6255 - Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase 2 trial.
Presenter: Joyce O'Shaughnessy
Session: Proffered Paper - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1470 - monarcHER: A randomized Phase 2 study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
Presenter: Sara Tolaney
Session: Proffered Paper - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Proffered Paper - Breast cancer, metastatic - Invited Discussant LBA22 and LBA23
Presenter: Mafalda Oliveira
Session: Proffered Paper - Breast cancer, metastatic
Resources:
Slides
Webcast